HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

SAFETY OF THERAPY WITH ANTIPSYCHOTICS: THE SEROTONIN RECEPTOR 2A (HTR2A) GENE AND METABOLIC DISORDERS

DOI: https://doi.org/10.29296/25877305-2019-01-07
Issue: 
1
Year: 
2019

L. Akhmetova(1, 2); M. Tolmachev(1); Professor N. Shnaider(1), MD; T. Potupchik(6), Candidate of Medical Sciences ; E. Ershov(1, 3); A. Bugorsky(3); V. Kravtsov(4); A. Taraskina(1), Candidate of Biological Sciences; Professor B. Andreev(4), MD; Professor K. Yakhin(5), MD; Professor N. Neznanov(1), MD; R. Nasyrova(1, 3), MD 1-V.M. Bekhterev National Medical Research Center of Psychiatry and Neurology, Saint Petersburg 2-Acad. V.M. Bekhterev Republican Clinical Mental Hospital, Kazan 3-P.P. Kashchenko Mental Hospital One, Saint Petersburg 4-Saint Petersburg State University 5-Kazan State Medical University 6-Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

The association of the HTR2A T102C (rs6313) polymorphism with anthropometric and biochemical markers was studied in patients receiving typical and atypical antipsychotics as monotherapy.

Keywords: 
therapy
psychiatry
antipsychotics
serotonin receptor HTR2A gene
metabolic disorders



References: 
  1. Zhang J., Malhotra A. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction // Exp. Opin. Drug Metab. Toxicol. – 2011; 7 (1): 9–37. DOI: 10.1517/17425255.2011.532787.
  2. Jones P., Barnes T., Davies L. et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) // Arch. Gen Psychiatry. – 2006; 63 (10): 1079–87.
  3. Nasyrova R.F., Ivanov M.V., Neznanov N.G. Vvedenie v psihofarmakogenetiku / SPb, 2015 [Nasyrova R.F., Ivanov M.V., Neznanov N.G. Vvedeniye v psikhofarmakogenetiku / SPb, 2015 (in Russ.)].
  4. Kuroki T., Nagao N., Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis // Prog. Brain Res. – 2008; 172: 199–212. DOI: 10.1016/S0079-6123(08)00910-2.
  5. Horacek J., Bubenikova-Valesova V., Kopecek M. et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia // CNS Drugs. – 2006; 20 (5): 389–409.
  6. Nasyrova R.F., Tolmachev M.Yu., Sychev D.A. i dr. Mehanizmy razvitiya antipsihotik-inducirovannyh metabolicheskih narusheniy: farmakogeneticheskiy aspekt // Byulleten` sibirskoy mediciny. – 2017; 16 (4): 30–41 [Nasyrova R.F., Tolmachev M.Yu., Sychev D.A. et al. Mechanisms of development of antipsychotic-induced metabolic disorders: pharmacogenetic aspect // Byulleten sibirskoy meditsiny. – 2017; 16 (4): 30–41 (in Russ.)]. https://DOI.org/10.20538/1682-0363-2017-4-30-41
  7. Lencz T., Robinson D., Napolitano B. et al. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia // Pharmacogenet. Genomics. – 2010; 20 (9): 569–72. DOI: 10.1097/fpc.0b013e32833ca24b
  8. Maslovskiy S.Yu., Kozlovskiy V.L. Antipsihotik-inducirovannyy nabor vesa: Vozmozhnosti farmakologicheskoy korrekcii // Zhurn. nevrol. i psihiat. im. S.S. Korsakova. – 2008; 108: 81–6 [Maslovsky S.YU., Kozlovsky V.L. Antipsychotic-induced weight gain: the possibilities of pharmacological correction // Zhurn. nevrol. i psikhiat. im. S.S. Korsakova. – 2008; 108: 81–6 (in Russ.)].
  9. Dickerson F., Brown C., Kreyenbuhl J. et al. Obesity among individuals with serious mental illness // Acta Psychiatr. Scand. – 2006; 113 (4): 306–13.
  10. Haslam D., James W. Obesity // Lancet. – 2005; 366 (9492): 1197–209.
  11. Kosataya M.A., Mar`ina A.V., Sergeeva A.V. i dr. Odnonukleotidnyy polimorfizm MTHFR677C>T i vyrazhennost` metabolicheskih pobochnyh e`ffektov antipsihotikov u bol`nyh shizofreniey: rezul`taty pilotnogo issledovaniya // Obozrenie psihiatrii i medicinskoy psihologii. – 2018; 3: 40–6 [Kosataya M.A., Marina A.V., Sergeeva A.V. et al. Single nucleotide polymorphism MTHFR677C>T and the severity of metabolic side effects of antipsychotics in patients with schizophrenia: the results of a pilot study // Obozreniye psikhiatrii i meditsinskoy psikhologii. – 2018; 3: 40–6 (in Russ.)]. DOI: 10.31363/2313-7053-2018-3-40-46
  12. Barnes N., Sharp T. A review of central 5-HT receptors and their function // Neuropharmacology. – 1999; 38 (8): 1083–152.
  13. Polesskaya O., Sokolov B. Differential expression of the “C” and “T” alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics // J. Neurosci. Res. – 2002; 67: 812–22.
  14. Myers R., Airey D., Manier D. et al. Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression // Biol. Psychiatry. – 2007; 61 (2): 167–73.
  15. Turecki G., Brière R., Dewar K. et al. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide // Am. J. Psychiatry. – 1999; 156 (9): 1456–8.
  16. Aghajanian G., Marek G. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells // Neuropharmacology. – 1997; 36 (4–5): 589–99.
  17. Lane H., Liu Y., Huang C. et al. Risperidone-related weight gain: genetic and nongenetic predictors // J. Clin. Psychopharmacol. – 2006; 26 (2): 128–34.
  18. Prado-Lima P., Cruz I., Schwanke C. et al. Human food preferences are associated with a 5-HT(2A) serotonergic receptor polymorphism // Mol. Psychiatry. – 2006; 11 (10): 889–91.
  19. Parsons M., D’Souza U., Arranz M. et al. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity // Biol. Psychiatry. – 2004; 56 (6): 406–10